The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict GlaxoSmithKline's revenues will expand 3.0% and EPS will increase 18.0%.
The average estimate for revenue is $11.19 billion. On the bottom line, the average EPS estimate is $1.05.
Last quarter, GlaxoSmithKline booked revenue of $10.52 billion. GAAP reported sales were 5.3% lower than the prior-year quarter's $11.11 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.84. GAAP EPS of $0.36 for Q3 were 16% lower than the prior-year quarter's $0.43 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 70.2%, 80 basis points worse than the prior-year quarter. Operating margin was 27.0%, 390 basis points worse than the prior-year quarter. Net margin was 17.2%, 220 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $43.23 billion. The average EPS estimate is $3.88.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 35 members out of 39 rating the stock outperform, and four members rating it underperform. Among two CAPS All-Star picks (recommendations by the highest-ranked CAPS members), two give GlaxoSmithKline a green thumbs-up, and give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on GlaxoSmithKline is outperform, with an average price target of $47.84.
- Add GlaxoSmithKline to My Watchlist.